A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

Jin Endo, Motoaki Sano, Yasuhiro Izumiya, Kenichi Tsujita, Kazufumi Nakamura, Nobuhiro Tahara, Koichiro Kuwahara, Takayuki Inomata, Mitsuharu Ueda, Yoshiki Sekijima, Yukio Ando, Hiroyuki Tsutsui, Mitsuaki Isobe, Keiichi Fukuda

研究成果: ジャーナルへの寄稿評論記事

1 引用 (Scopus)

抜粋

Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

元の言語英語
ページ(範囲)15-17
ページ数3
ジャーナルCirculation Journal
84
発行部数1
DOI
出版物ステータス出版済み - 1 1 2019

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

これを引用

Endo, J., Sano, M., Izumiya, Y., Tsujita, K., Nakamura, K., Tahara, N., ... Fukuda, K. (2019). A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. Circulation Journal, 84(1), 15-17. https://doi.org/10.1253/circj.CJ-19-0811